Dinapsoline| CAS#458563-40-1| recepto| MedKoo

MedKoo Cat#: 565464 | Name: Dinapsoline

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dinapsoline is a drug developed for the treatment of Parkinson's disease, that acts as a selective full agonist at the dopamine D1 receptor.

Chemical Structure

Dinapsoline

CAS#458563-40-1

Theoretical Analysis

MedKoo Cat#: 565464

Name: Dinapsoline

CAS#: 458563-40-1

Chemical Formula: C16H15NO2

Exact Mass: 253.1103

Molecular Weight: 253.30

Elemental Analysis: C, 75.87; H, 5.97; N, 5.53; O, 12.63

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Dinapsoline;

IUPAC/Chemical Name

(S)-2,3,7,11b-Tetrahydro-1H-dibenzo[de,h]isoquinoline-8,9-diol

InChi Key

ZQTSNGJHMUKLOM-ZDUSSCGKSA-N

InChi Code

InChI=1S/C16H15NO2/c18-14-5-4-11-12(16(14)19)6-9-2-1-3-10-7-17-8-13(11)15(9)10/h1-5,13,17-19H,6-8H2/t13-/m0/s1

SMILES Code

OC1=C2CC3=C4C(CNC[C@@]4([H])C2=CC=C1O)=CC=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 253.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Fowler JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB. Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations. Mol Pharmacol. 2012 Jun;81(6):820-31. doi: 10.1124/mol.111.075457. Epub 2012 Mar 13. PubMed PMID: 22416052; PubMed Central PMCID: PMC3362898. 2: Zhang J, Xiong B, Zhen X, Zhang A. Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev. 2009 Mar;29(2):272-94. doi: 10.1002/med.20130. Review. PubMed PMID: 18642350. 3: Ryman-Rasmussen JP, Griffith A, Oloff S, Vaidehi N, Brown JT, Goddard WA 3rd, Mailman RB. Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors. Neuropharmacology. 2007 Feb;52(2):562-75. Epub 2006 Oct 24. PubMed PMID: 17067639; PubMed Central PMCID: PMC1855220. 4: Gleason SD, Witkin JM. Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine. Psychopharmacology (Berl). 2006 May;186(1):25-31. Epub 2006 Mar 31. PubMed PMID: 16575553. 5: Ryman-Rasmussen JP, Nichols DE, Mailman RB. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol. 2005 Oct;68(4):1039-48. Epub 2005 Jun 28. PubMed PMID: 15985612. 6: Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol. 2004 Jul;66(1):97-105. PubMed PMID: 15213300. 7: Gleason SD, Witkin JM. Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393. Behav Pharmacol. 2004 Feb;15(1):85-9. PubMed PMID: 15075630. 8: Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, Nichols DE. 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. Bioorg Med Chem. 2004 Mar 15;12(6):1403-12. PubMed PMID: 15018913. 9: Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB. Synthesis and SAR exploration of dinapsoline analogues. Bioorg Med Chem. 2004 Feb 15;12(4):715-34. PubMed PMID: 14759732. 10: Qandil AM, Lewis MM, Jassen A, Leonard SK, Mailman RB, Nichols DE. Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands. Bioorg Med Chem. 2003 Apr 3;11(7):1451-64. PubMed PMID: 12628671. 11: Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G. (+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist. J Med Chem. 2002 Aug 15;45(17):3660-8. PubMed PMID: 12166939. 12: Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. J Pharmacol Exp Ther. 2001 Feb;296(2):338-44. PubMed PMID: 11160615. 13: Doll MK, Nichols DE, Kilts JD, Prioleau C, Lawler CP, Lewis MM, Mailman RB. Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane. J Med Chem. 1999 Mar 11;42(5):935-40. PubMed PMID: 10072690. 14: Lewis MM, Watts VJ, Lawler CP, Nichols DE, Mailman RB. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther. 1998 Jul;286(1):345-53. PubMed PMID: 9655879. 15: Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. J Med Chem. 1996 Jan 19;39(2):549-55. PubMed PMID: 8558526.